Lake Street Capital Markets LLC
09/17/2026 | Press release | Distributed by Public on 09/17/2026 09:01
Spruce Biosciences, Inc. (SPRB) - Initiation of Coverage
Lake Street Capital Markets Analyst, Daniel Brims, Ph.D., initiated coverage of Spruce Biosciences, Inc. with a BUY rating and price target of $149 (SPRB-$149). Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B.
Want to stay up-to-date with the latest at Lake Street? Subscribe to our mailing list!
NameEmail Address
Thanks for joining our mailing list.
Oops! Something went wrong while submitting the form.
Lake Street Capital Markets LLC published this content on September 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 17, 2026 at 15:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]